All of the shares of common stock were offered and sold by Discovery Labs pursuant to an effective registration statement previously filed with the Securities and Exchange Commission.
Discovery Laboratories is a biotechnology company developing surfactant replacement therapies (SRT) for respiratory diseases. Discovery Labs’ technology produces a precision-engineered surfactant that is designed to closely mimic the essential properties of natural human lung surfactant.